<DOC>
	<DOCNO>NCT01704703</DOCNO>
	<brief_summary>Open label Phase II study FOLFIRI + Panitumumab use ultra-selection technology next generation high sensitivity genotyping patient stage IV colorectal cancer refractory irinotecan without mutation KRAS , PIK3Ca , BRAF NRAS gene detect highly sensitive technique .</brief_summary>
	<brief_title>Study FOLFIRI + Panitumumab Using Ultra-selection Technology Patients With Stage IV Colorectal Cancer Refractory Irinotecan Without Any Mutation KRAS , PIK3Ca , BRAF NRAS Genes Detected With Highly Sensitive Techniques</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Competent understand , sign date IECapproved inform consent form . 2 . Men woman 18 year age old time write informed consent obtain . 3 . Histologically confirm metastatic adenocarcinoma colon rectum WildType RAS ( No mutation ) least 1 measurable metastatic lesion follow RECIST criterion v 1.1 initially irresectable ( non suitable radical surgery inclusion time ) . 4 . Obtention DNA tumor tissue block send central lab ( ICO ) amenable highly sensitive technique 5 . Previous irinotecan base chemotherapy +/ bevacizumab metastatic CCR least 6 week . 6 . Irinotecan base chemotherapy need recent chemotherapy administrate . There restriction number treatment line study inclusion . 7 . Disease progression irinotecan treatment within 6 month irinotecan treatment . 8 . Karnofsky status ≥ 70 % . 9 . Adequate bone marrow , hepatic , renal metabolic function , 1 . Adequate bone marrow function : neutrophil ≥ 1.5x109/ L ; platelet ≥ 100x109/L ; hemoglobin ≥ 9g/dL . 2 . Hepatic function follow : total bilirubin count ≤ 1.5 x ULN ; ALAT ASAT ≤ 2.5 x ULN ( ≤ 5 x ULN case liver metastasis ) . 3 . Renal function : creatinine clearance &gt; 50 ml/min ( accord Cockcroft Gault formula ) 4 . Metabolic function : magnesium ≥ low limit normal ( LIN ) 10 . Life expectancy ≥ 3 month . 1 . Prior malignant tumor last 5 year , except history basal cell carcinoma skin preinvasive cervical cancer . 2 . Unresolved toxicity prior systemic therapy and/or radiotherapy , opinion investigator , qualify patient inclusion . 3 . Documented suspected central nervous system metastasis . 4 . Any previous antitumoral treatment ( chemotherapy , hormonal therapy , radiation treatment , surgery , immunotherapy , biologic therapy ) ≤ 28 day study inclusion . 5 . Significant cardiovascular disease include unstable angina myocardial infarction within 12 month initiate study treatment history ventricular arrhythmia . 6 . Prior antiEGFr antibody therapy ( eg , Cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( eg , Erlotinib ) . Subjects discontinue first dose antiEGFR therapy ( Cetuximab ) infusion reaction may participate clinical trial . 7 . Paraffinembedded tissue unstained tumor slide primary metastatic tumor available quality ADN available biomarker determination highly sensitive technique . 8 . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis . 9 . Treatment systemic infection within 14 day study inclusion . 10 . Acute subacute intestinal occlusion /or active inflammatory bowel disease bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) . 11 . History Gilbert 's syndrome dihydropyrimidine deficiency . 12 . History medical condition may increase risk associate study participation may interfere interpretation study result . 13 . Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection . 14 . Subject allergic ingredient study medication Staphylococcus protein A . 15 . Any comorbid disease would increase risk toxicity . 16 . Any kind disorder compromise ability subject give write informed consent and/or comply study procedure . 17 . Subject pregnant breast feeding . 18 . Surgery ( exclude diagnostic biopsy central venous catheter placement ) ≤ 28 day prior study inclusion . 19 . Woman man childbearing potential consenting use adequate contraceptive precaution . 20 . Subject unwilling unable comply study requirement . 21 . Psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>KRAS , PIK3Ca , BRAF NRAS gene</keyword>
	<keyword>highly sensitive technique</keyword>
</DOC>